Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - caspofungin -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - caspofungin -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - metaraminol tartrate, quantity: 19 mg (equivalent: metaraminol, qty 10 mg) - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; disodium edetate; citric acid monohydrate; water for injections; sodium chloride - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - voriconazole -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - aspirin, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch - for inhibition of platelet aggregation to help prevent heart attack and stroke in patients with known cardiovascular and cerebrovascular disease

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - ethanol, quantity: 79.5 % w/w - gel - excipient ingredients: carbomer copolymer (type b); purified water; trolamine; glycerol - antiseptic hand rub. hygienic hand rub. healthcare personnel antiseptic hand rub

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - fosfomycin trometamol, quantity: 5.631 g - granules - excipient ingredients: saccharin; sucrose; flavour - monurol is indicated only for the treatment of acute uncomplicated lower urinary tract infections (acute cystitis) in females above 12 years of age caused by the following susceptible pathogens: escherichia coli or, enterococcus faecalis.,monurol is not indicated for the treatment of pyelonephritis or perinephric abscess or where resistance is likely (previous treatment failure, infection due to non-susceptible organism).,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to monurol. however, therapy may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. consideration should be given to the relevant clinical guidelines on the appropriate use of antibacterial agents.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - 47671 - epidermal osmotic dressing, non-sterile - osmotic drawing gel

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - silodosin, quantity: 8 mg - capsule, hard - excipient ingredients: mannitol; sodium lauryl sulfate; magnesium stearate; gelatin; titanium dioxide; pregelatinised maize starch - urorec is indicated for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia in adult men